Is There a Prognostic Difference Between Stage IIIA Subgroups in Lung Cancer?

Area of Science:

• Oncology
• Thoracic Surgery
• Cancer Research

Background:

• Stage IIIA lung cancer encompasses a heterogeneous patient group, making treatment strategies controversial.
• Surgical management of stage IIIA lung cancer necessitates clear prognostic stratification.

Purpose of the Study:

• To compare survival rates between distinct stage IIIA lung cancer subgroups.
• To externally validate a prognostic model for stage IIIA lung cancer using an independent dataset.

Main Methods:

• Retrospective analysis of 424 stage IIIA and 82 stage IIIB lung cancer patients undergoing complete resection.
• Stage IIIA was categorized into IIIA-T (tumor-dominant) and IIIA-N2 (node-dominant) subgroups.
• A prognostic model was developed and validated in an external cohort.

Main Results:

• Multivariate analysis identified age, stage IIIB, and pN2 as independent negative prognostic factors.
• Five-year survival was 51.3% for IIIA-T versus 25.7% for IIIA-N2 patients (P < .0001).
• No significant survival difference was observed between IIIA-N2 and stage IIIB groups (25.7% vs 25.3%, P = .442).

Conclusions:

• A significant prognostic difference exists between stage IIIA lung cancer subgroups.
• The IIIA-T subgroup demonstrates superior survival outcomes compared to the IIIA-N2 subgroup.
• The validated model can aid in stratifying stage IIIA lung cancer patients for surgical treatment.